<?php
include_once('.././common.php');
include_once(G5_PATH . '/head.php');
?>

<div id="providers" class="sub02">
  <section class="sub-visual visual02 el">
    <div class="visual-txt">
      <h2><?= $title ?></h2>
    </div>
  </section>
  <!--sub-visual-->
  <section class="top">
    <div class="inner">
      <h2 class="cont-tit">Clinical Data</h2>
      <div class="explan">
        <p>Learn more about regdanvimab’s clinical and safety data. Regdanvimab
          also showed neutralization potency on viral variants through in vitro
          data and in vivo animal tests, separate from the pivotal studies.</p>
      </div>
      <div class="cont-sec">
        <table class="table-style01">
          <thead>
          <tr>
            <th>Healthy Subjects</th>
            <th colspan="3">Mild to Moderate Patients</th>
            <th>Variant Tests</th>
          </tr>
          </thead>
          <tbody>
          <tr>
            <td class="cate">1.1 Healthy Volunteer Study (Phase I)</td>
            <td class="cate">1.2 Mild COVID-19 Study (Phase I)</td>
            <td class="cate" colspan="2">3.2 Global Pivotal Study (Phase
              II/III)
            </td>
            <td class="cate">Neutralizing Capability against Emerging Variants
            </td>
          </tr>
          <tr>
            <td class="cate2">Dose Finding</td>
            <td class="cate2">Dose Finding</td>
            <td class="cate2">Part1</td>
            <td class="cate2">Part2</td>
            <td class="cate2">-</td>
          </tr>
          <tr>
            <td>Regdanvimab was well tolerated in the study population of
              healthy subjects.
            </td>
            <td>Regdanvimab was well tolerated, and there were no clinically
              significant safety issues in mild covid-19 patients.
            </td>
            <td>Regdanvimab reduced progression rates to severe COVID-19 by 54%
              for patients with mild-to-moderate symptoms and 68% for moderate
              patients aged 50 years and over.
            </td>
            <td>Progression of COVID-19 at Day 28 was reduced by 72% in
              high-risk patients treated with regdanvimab compared to placebo (p&lt;0.0001).
            </td>
            <td>In vitro and in vivo animal tests show that regdanvimab retained
              neutralizing potency in the wild type and variants of
              concern including the Alpha (B.1.17), Beta (B.1.351), Gamma (P.1)
              and Delta (B.1.167.2) variants.
            </td>
          </tr>
          <tr>
            <td><a href="#sec01" class="detail-btn">See Details</a></td>
            <td><a href="#sec02" class="detail-btn">See Details</a></td>
            <td><a href="#sec03" class="detail-btn">See Details</a></td>
            <td><a href="#sec04" class="detail-btn">See Details</a></td>
            <td><a href="#sec05" class="detail-btn">See Details</a></td>
          </tr>
          </tbody>
        </table>
      </div>
    </div>
  </section>
  <!--top-->
  <section id="sec01" class="cont-a el">
    <div class="inner">
      <h2 class="cont-tit">Phase I 1.1 Healthy Volunteer Study (<a
          href="https://clinicaltrials.gov/ct2/show/NCT04525079"
          style="text-decoration:underline #302f86; color: #302f86;"
          target="_blank">NCT04525079</a>)<span class="s-num">1-3</span></h3>
        <div class="cont-sec">
          <h3 class="sub-tit">Study Design</h3>
          <ul class="cont-list cont-indt">
            <li>A Phase 1, Randomized, Double-blind, Placebo-controlled,
              Parallel Group, Single Ascending Dose Study
            </li>
          </ul>
        </div>
        <div class="img-sec">
          <img src="/img/providers/des_img01.png">
          <p>*Reviewed and approved by the Dose Escalation Committee </p>
        </div>
        <div class="cont-sec">
          <h3 class="sub-tit">Primary Objective</h3>
          <div class="cont-indt">
            <div class="cont-box">
              <ul class="cont-list">
                <li>To evaluate the preliminary <b>safety and tolerability</b>
                  of regdanvimab up to Day 14 of the last enrolled subject
                </li>
              </ul>
            </div>
          </div>
        </div>
        <div class="cont-sec">
          <h3 class="sub-tit">Primary Endpoint</h3>
          <div class="cont-indt">
            <div class="cont-box">
              <ul class="cont-list">
                <li>Primary safety outcome [Time Frame: Day 14]</li>
                <li>Treatment-emergent adverse events (TEAEs)</li>
                <li>Treatment-emergent serious AEs (TESAEs)</li>
                <li>Treatment-emergent AEs of special interest (TEAESI; infusion
                  related reactions including hypersensitivity/anaphylactic
                  reaction)
                </li>
              </ul>
            </div>
          </div>
        </div>
    </div>
    <!---->
    <section class="cont-b">
      <div class="inner">
        <h3 class="sub-tit">Study Results</h3>
        <h3 class="sub-tit3">Study Demographic</h3>
        <div class="cont-indt">
          <div class="cont-box">
            <ul class="cont-list">
              <li>In general, the demographics were well distributed between the
                treatment groups.
              </li>
              <li>All subjects were male and Asian (n = 32; 100%).</li>
            </ul>
          </div>
        </div>
        <h3 class="sub-tit3">Safety</h3>
        <div class="cont-indt">
          <div class="cont-box">
            <ul class="cont-list">
              <li>There were a total of 4 TEAEs in 4 subjects (n = 4; 12.5%) up
                to Day 14 of the last enrolled subject.
              </li>
              <li>All TEAEs were considered as related, grade 1 in Intensity and
                recovered.
              </li>
              <li>There was 1 TEAESI of infusion related reaction in cohort 3 (n
                = 1; 12.5%).
              </li>
              <li>There were no TESAEs or adverse events leading to study
                discontinuation.
              </li>
              <li>Overall, regdanvimab was well tolerated in the study
                population of healthy subjects.
              </li>
            </ul>
          </div>
          <p class="p-bk">TEAE, treatment-emergent adverse event; TEAESI,
            treatment-emergent adverse event of special interest; TESAE,
            treatment-emergent serious adverse event.</p>
        </div>
      </div>
    </section>
    <!--cont-b-->
  </section>
  <!--sec01-->
  <section id="sec02" class="cont-c el">
    <div class="inner">
      <h2 class="cont-tit">Phase I 1.2 Mild COVID-19 Study (<a
          href="https://clinicaltrials.gov/ct2/show/NCT04593641?cond=NCT04593641&draw=2&rank=1"
          style="text-decoration:underline #302f86; color: #302f86;"
          target="_blank">NCT04593641</a>)<span class="s-num">2-5</span></h2>
      <div class="cont-sec">
        <h3 class="sub-tit">Study Results</h3>
        <ul class="cont-list cont-indt">
          <li>A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled,
            Parallel Group, Single Ascending Dose Study
          </li>
        </ul>
      </div>
      <div class="img-sec">
        <img src="/img/providers/des_img03.png">
        <p>*Reviewed and approved by the Dose Escalation Committee </p>
      </div>
      <!--Study Design-->
      <div class="cont-sec">
        <h3 class="sub-tit">Objectives</h3>
        <div class="cont-box cont-indt">
          <ul class="cont-list">
            <li>Primary objective: To evaluate the preliminary <b>safety and
                tolerability</b> of regdanvimab up to Day 14 of the last
              enrolled patient
            </li>
            <li>Secondary objective: To evaluate the <b>viral efficacy and
                characterization of SARS-CoV-2 viral isolates, efficacy, PK and
                additional safety</b>
              of regdanvimab including immunogenicity
            </li>
          </ul>
        </div>
      </div>
      <!--Objectives-->
      <div class="cont-sec">
        <h3 class="sub-tit">Primary Endpoints</h3>
        <div class="cont-box cont-indt">
          <ul class="cont-list">
            <li>Primary safety outcome [Time Frame: Day 14]</li>
            <li>Treatment-emergent adverse events (TEAEs)</li>
            <li>Treatment-emergent serious AEs (TESAEs)</li>
            <li>Treatment-emergent AEs of special interest (TEAESI; infusion
              related reactions including hypersensitivity/anaphylactic
              reaction)
            </li>
          </ul>
        </div>
      </div>
      <!--Primary Endpoints-->
      <div class="cont-sec">
        <h3 class="sub-tit">Key Secondary Endpoints</h3>
        <div class="cont-box cont-indt">
          <ul class="cont-list">
            <li>Virology: Viral shedding in nasopharyngeal swab specimens based
              on qPCR and cell culture
            </li>
            <li>Efficacy: Time to clinical recovery up to Day 28</li>
          </ul>
        </div>
      </div>
      <!--Key Secondary Endpoints-->
    </div>
    <!---->
    <section class="cont-d">
      <div class="inner">
        <div class="cont-sec">
          <h3 class="sub-tit">Study Results</h3>
          <h3 class="sub-tit3">Study Demographics</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li>
                Median age was slightly higher in the regdanvimab 20 mg/kg group
                (59.0 years compared to 52.0 years in all patients),
                but in general the demographics were well matched between the
                treatment groups.
              </li>
              <li>All patients in cohort 1 were Asian and all patients in cohort
                2 and 3 were Caucasian.
              </li>
            </ul>
          </div>
        </div>
        <!--Study Demographics-->
        <div class="cont-sec">
          <h3 class="sub-tit3">Safety</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li>There were a total of 19 TEAEs in 11 subjects (n = 11 [61.1%])
                up to Day 14 of the last enrolled patient.
              </li>
              <li>All TEAEs were considered as unrelated.</li>
              <li>There were no TESAEs, TEAESI or adverse events leading to
                study discontinuation.
              </li>
              <li>Overall, regdanvimab was well tolerated in the study
                population of patients with mild SARS-CoV-2 infection.
              </li>
            </ul>
          </div>
        </div>
        <!--Safety-->
        <div class="cont-sec">
          <h3 class="sub-tit3">Time to Clinical Recovery up to Day 14</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li><b>Time to clinical recovery was <span
                    class="p-gr">7 days</span> in Placebo and <span
                    class="p-gr">3.5 day</span> in regdanvimab 40mg/kg arm.</b>
              </li>
            </ul>
            <div class="table-wr">
              <table class="table-style02">
                <thead>
                <tr>
                  <th colspan="2">Category</th>
                  <th>Placebo<br>(N=3)</th>
                  <th>regdanvimab<br>20 mg/kg (N=5)</th>
                  <th>regdanvimab<br>40 mg/kg (N=5)</th>
                  <th>regdanvimab<br>80 mg/kg (N=5)</th>
                  <th>regdanvimab Total<br>(N=15)</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                  <td class="cate"><b>Age(years)</b></td>
                  <td class="cate">Median (range)</td>
                  <td>50.0 (49, 57)</td>
                  <td>59.0 (49, 61)</td>
                  <td>51.0 (25, 52)</td>
                  <td>52.0 (29, 59)</td>
                  <td>54.0 (25, 61)</td>
                </tr>
                <tr>
                  <td class="cate"><b>Time from symptom onset to study drug<br>administration
                      (days)</b></td>
                  <td class="cate">Median (range)</td>
                  <td bgcolor="#f7f7f7">3 (2,4)</td>
                  <td bgcolor="#f7f7f7">3 (2,4)</td>
                  <td bgcolor="#f7f7f7">5 (3,6)</td>
                  <td bgcolor="#f7f7f7">3 (2,5)</td>
                  <td bgcolor="#f7f7f7">3 (2,6)</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="2"><b>Time to clinical recovery
                      (days)</b></td>
                  <td class="cate">Mean</td>
                  <td><b class="p-rd">7</b></td>
                  <td><b class="p-rd">4.7</b></td>
                  <td><b class="p-rd">3.5</b></td>
                  <td><b class="p-rd">3.5</b></td>
                  <td><b class="p-rd">3.9</b></td>
                </tr>
                <tr>
                  <td class="cate">Median (range)</td>
                  <td>2 (1, 18)</td>
                  <td>4.0 (2.0, 7.5)</td>
                  <td>2.0 (0.5, 8.5)</td>
                  <td>3.5 (1.5, 5.5)</td>
                  <td>3.5 (0.5, 8.5)</td>
                </tr>
                <tr>
                  <td class="cate"><b>Hospitalization or antiviral therapy<br>due
                      to aggravation of COVID-19</b></td>
                  <td class="cate">N/Total N (%)</td>
                  <td>1/3 (33.3%)</td>
                  <td>0</td>
                  <td>0</td>
                  <td>0</td>
                  <td>0</td>
                </tr>
                </tbody>
              </table>
            </div>
            <ul class="cont-list">
              <li>
                Clinical recovery is defined by all symptoms on the SARS-CoV-2
                infection symptom Checklist (consists of 7 symptoms and the
                intensity of patient’s self-aware for each. symptom) are
                recorded as ‘absent or mild in intensity’ for at least 24 hours.
              </li>
              <li>Regdanvimab is not authorized with doses of 20 mg/kg and 80
                mg/kg.
              </li>
              <li class="blt-none"><b class="p-bk">TEAE, treatment-emergent
                  adverse event; TEAESI, treatment-emergent adverse event of
                  special interest.</b></li>
            </ul>
          </div>
        </div>
        <!---->
        <div class="cont-sec">
          <h3 class="sub-tit3">Viral shedding based on qPCR up to Day 7
            (N=18)</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li>The mean changes from baseline for viral shedding in
                nasopharyngeal swab specimens based on qPCR in the regdanvimab
                treatment groups were generally greater than the Placebo group.
              </li>
              <li>In general, patients with max viral titer over 5 log<span
                  class="s-txt v-btm">10</span>cp/mL based on qPCR had greater
                reductions in viral shedding up to Day 7 after receiving
                regdanvimab than Placebo.
              </li>
            </ul>
            <div class="img-sec"><img src="/img/providers/graph_img01.jpg">
            </div>
            <div class="table-wr">
              <table class="table-style02">
                <thead>
                <tr>
                  <th colspan="2"></th>
                  <th>&lt;10^5 cp/mL (N=<span class="p-bl">0</span>/<span
                      class="p-dgr">3</span>/<span class="p-rd">1</span>/<span
                      class="p-bk">2</span>)
                  </th>
                  <th>&gt;10^5 cp/mL (N=<span class="p-bl">5</span>/<span
                      class="p-dgr">2</span>/<span class="p-rd">4</span>/<span
                      class="p-bk">1</span>)
                  </th>
                  <th>&gt;10^6 cp/mL (N=<span class="p-bl">4</span>/<span
                      class="p-dgr">2</span>/<span class="p-rd">3</span>/<span
                      class="p-bk">1</span>)
                  </th>
                  <th>&gt;10^7cp/mL (N=<span class="p-bl">3</span>/<span
                      class="p-dgr">2</span>/<span class="p-rd">3</span>/<span
                      class="p-bk">1</span>)
                  </th>
                </tr>
                <thead>
                <tbody>
                <tr>
                  <td class="cate" rowspan="4">Mean value<br>of max viral
                    titer<br>(+-SE in log<span class="sb-script v-btm">10</span>
                    cp/ml)
                  </td>
                  <td>regdanvimab 20 mg/kg</td>
                  <td>N/A</td>
                  <td>6.74 (0.388)</td>
                  <td>7.09 (0.239)</td>
                  <td>7.30 (0.148)</td>
                </tr>
                <tr>
                  <td>regdanvimab 40 mg/kg</td>
                  <td>2.97(0.273)</td>
                  <td>8.21 (0.410)</td>
                  <td>8.21 (0.410)</td>
                  <td>8.21 (0.410)</td>
                </tr>
                <tr>
                  <td>regdanvimab 80 mg/kg</td>
                  <td>2.83</td>
                  <td>6.84 (0.461)</td>
                  <td>7.70 (0.088)</td>
                  <td>7.30 (0.088)</td>
                </tr>
                <tr>
                  <td>Placebo</td>
                  <td>4.13 (0.695)</td>
                  <td>7.41</td>
                  <td>7.41</td>
                  <td>7.41</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="4">Area under curve<br>of viral
                    titer<br>(log<span class="sb-script v-btm">10</span>
                    cp/ml*day)
                  </td>
                  <td>regdanvimab 20 mg/kg</td>
                  <td>N/A</td>
                  <td>28.42</td>
                  <td>29.09</td>
                  <td>31.15</td>
                </tr>
                <tr>
                  <td>regdanvimab 40 mg/kg</td>
                  <td>9.35</td>
                  <td>31.83</td>
                  <td>31.83</td>
                  <td>31.83</td>
                </tr>
                <tr>
                  <td>regdanvimab 80 mg/kg</td>
                  <td>7.63</td>
                  <td>32.24</td>
                  <td>33.62</td>
                  <td>33.62</td>
                </tr>
                <tr>
                  <td>Placebo</td>
                  <td>13.70</td>
                  <td>44.22</td>
                  <td>44.22</td>
                  <td>44.22</td>
                </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>
      </div>
    </section>
    <!--cont-d-->
  </section>
  <!--sec02-->
  <section id="sec03" class="cont-e el">
    <div class="inner">
      <h2 class="cont-tit">Part 1 of Phase II/III Global Pivotal Study (<a
          href="https://clinicaltrials.gov/ct2/show/NCT04602000?cond=CT-P59&draw=2&rank=2"
          style="text-decoration:underline #302f86; color: #302f86;"
          target="_blank">NCT04602000</a>)<span class="s-num">6, 7</span></h2>
      <div class="cont-sec">
        <h3 class="sub-tit">Study Design</h3>
        <div class="cont-indt">
          <ul class="cont-list">
            <li><b>A Randomized, Parallel-group, Placebo-controlled,
                Double-blind study</b></li>
            <li>The data supporting regdanvimab's authorization are based on
              interim data from one Phase 2 trial of 307 mild to moderate
              COVID-19 patients.
            </li>
            <li>This study is designed to evaluate the efficacy and safety of
              regdanvimab in combination with standard of care in outpatients
              with SARS-CoV-2 infection.
            </li>

          </ul>
          <div class="img-sec mgt20"><img src="/img/providers/part_img01.png">
          </div>
        </div>
      </div>
      <!--Study Design : Part 1-->
    </div>
  </section>
  <!--sec03-->
  <section id="sec04" class="cont-e el">
    <div class="inner">
      <h2 class="cont-tit">Part 2 of Phase II/III Global Pivotal Study (<a
          href="https://clinicaltrials.gov/ct2/show/NCT04602000?cond=CT-P59&draw=2&rank=2"
          style="text-decoration:underline #302f86; color: #302f86;"
          target="_blank">NCT04602000</a>)<span class="s-num">8</span></h2>
      <div class="cont-sec">
        <h3 class="sub-tit">Study Design</h3>
        <div class="cont-indt">
          <ul class="cont-list">
            <li><b>A Randomized, Parallel-group, Placebo-controlled,
                Double-blind study</b></li>
            <li>The data supporting regdanvimab's authorization are based on
              interim data from one Phase 3 trial of 1315 mild to moderate
              COVID-19 patients.
            </li>
            <li>This study is designed to evaluate the efficacy and safety of
              regdanvimab in combination with standard of care in outpatients
              with SARS-CoV-2 infection.
            </li>

          </ul>
          <div class="img-sec mgt20"><img src="/img/providers/part_img02.png">
          </div>
        </div>
      </div>
      <!--Study Design : Part 2-->
      <div class="cont-sec">
        <h3 class="sub-tit">Primary Endpoints</h3>
        <div class="cont-box cont-indt">
          <b class="p-bk mg06">Key Primary Endpoint</b>
          <ul class="cont-list mg20">
            <li>
              Proportion of patients with clinical symptom requiring
              hospitalisation, oxygen therapy or experiencing mortality due to
              SARS-CoV-2 infection up to Day 28 in high-risk patients*
            </li>
          </ul>
          <b class="p-bk mg06">Supportive Primary Endpoints</b>
          <ul class="cont-list">
            <li>Proportion of patients with negative conversion in
              nasopharyngeal swab
            </li>
            <li>specimen based on RT-qPCR or cell culture at each visit up to
              Day 14
            </li>
            <li>Time to negative conversion in nasopharyngeal swab specimen
              based on RT-PCR or cell culture up to Day 14
            </li>
            <li>Time to clinical recovery up to Day 14</li>
          </ul>
        </div>
      </div>
      <!--Primary Endpoints-->
      <div class="cont-sec">
        <h3 class="sub-tit">Eligibility Criteria</h3>
        <div class="cont-box cont-indt">
          <div class="dia-wr">
            <div class="list">
              <p class="tit01">Key Inclusion Criteria</p>
              <ul class="cont-list">
                <li>Adult male or female, aged <b>18 years or older</b>
                <li>
                <li>Patient <b>diagnosed with SARS-CoV-2</b> at screening</li>
                <li>
                  Patient with oxygen saturation <b>>94%</b> on room air and <b>not
                    requiring supplemental oxygen.</b> Patient with clinical
                  signs of pneumonia but no signs of severe pneumonia at the
                  investigator’s discretion is eligible for this study.
                </li>
                <li>Patient whose <b>onset of symptom is no more than 7 days</b>
                </li>
                <li>
                  Patient with 1≥ of the following (but not limited to)
                  SARS-CoV-2 associated symptoms within but not more than 7 days
                  prior to the study drug administration
                </li>
                <li class="blt-none">
                  <ul class="s-cont-list">
                    <li class="bt-none">
                      - Feeling feverish<br>
                      - Cough<br>
                      - Shortness of breath<br>
                      - Sore throat
                    </li>
                    <li class="bt-none">
                      - Body or muscle pain<br>
                      - Fatigue<br>
                      - Headache
                    </li>
                  </ul>
                  <!--s-cont-list-->
                </li>
              </ul>
              <!--cont-list-->
            </div>
            <div class="list">
              <p class="tit02">Key Exclusion Criteria</p>
              <ul class="cont-list">
                <li>Patient with <b>serious condition</b> (previously or
                  currently hospitalized, or requires hospitalization for
                  treatment of serious SARS-CoV-2 related conditions,
                  respiratory distress with respiratory rate ≥30 breaths/min,
                  requires supplemental oxygen, experience shock, complicated
                  with other organ failure and ICU treatment is needed, or any
                  other conditions suspected of being severe symptoms of
                  SARS-CoV-2)
                <li>
                <li>
                  Patient who has received or has plan to <b>receive any
                    prohibited medications or treatments</b>
                </li>
                <li>
                  Patient who has <b>known allergy or hypersensitivity reaction
                    to any monoclonal antibody</b> or to any components of the
                  study drug
                </li>
              </ul>
              <!--cont-list-->
            </div>
          </div>
        </div>
      </div>
      <!--Eligibility Criteria-->
    </div>
    <section class="cont-f">
      <div class="inner">
        <div class="cont-sec">
          <h3 class="sub-tit">Study Results</h3>
          <h3 class="sub-tit3">Key Demographic Information_Intent-to-Treat
            Infected (ITTI) set.</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li>66% of the enrolled patients were patients at high-risk*.</li>
            </ul>
            <div class="table-wr">
              <table class="table-style01">
                <thead>
                <tr>
                  <th colspan="2"></th>
                  <th>Total(N=1315)</th>
                  <th>regdanvimab 40 mg/kg (N=656)</th>
                  <th>Placebo (N=659)</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                  <td class="cate">Age(years)</td>
                  <td class="cate2">Median (min-max)</td>
                  <td>48 (18-87)</td>
                  <td>49 (18-87)</td>
                  <td>47 (18-83)</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="2">Sex, n (%)</td>
                  <td class="cate2">Male</td>
                  <td>674 (51.3)</td>
                  <td>347 (52.9)</td>
                  <td>327 (49.6)</td>
                </tr>
                <tr>
                  <td class="cate2">Female</td>
                  <td>641 (48.7)</td>
                  <td>309 (47.1)</td>
                  <td>332 (50.4)</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="6">Race, n (%)</td>
                  <td class="cate2">White</td>
                  <td>1132 (86.1)</td>
                  <td>563 (85.8)</td>
                  <td>569 (86.3)</td>
                </tr>
                <tr>
                  <td class="cate2">Black or African American</td>
                  <td>7 (0.5)</td>
                  <td>6 (0.9)</td>
                  <td>1 (0.2)</td>
                </tr>
                <tr>
                  <td class="cate2">American Indian or<br> Alaska Native</td>
                  <td>14 (1.1)</td>
                  <td>5 (0.8)</td>
                  <td>9 (1.4)</td>
                </tr>
                <tr>
                  <td class="cate2">Asian</td>
                  <td>14 (1.1)</td>
                  <td>7 (1.1)</td>
                  <td>7 (1.1)</td>
                </tr>
                <tr>
                  <td class="cate2">Native Hawaiian or<br> Other Pacific
                    Islander
                  </td>
                  <td>1 (0.1)</td>
                  <td>1 (0.2)</td>
                  <td>0</td>
                </tr>
                <tr>
                  <td class="cate2">Other</td>
                  <td>147 (11.2)</td>
                  <td>74 (11.3)</td>
                  <td>73 (11.1)</td>
                </tr>
                <tr>
                  <td class="cate">BMI (kg/m2)</td>
                  <td class="cate2">Mean (SD)</td>
                  <td>28.04 (5.369)</td>
                  <td>28.10 (5.149)</td>
                  <td>27.98 (5.583)</td>
                </tr>
                <tr>
                  <td class="cate">High-risk, n (%)</td>
                  <td class="cate2"></td>
                  <td class="bd-blue"><b class="p-bl">880 (66.9)</b></td>
                  <td>446 (68.0)</td>
                  <td>434 (65.9)</td>
                </tr>
                </tbody>
              </table>
            </div>
            <ul class="cont-list">
              <li>The patients having pneumonia symptoms were considered to have
                moderate disease severity of SARS-CoV-2 infection at Screening.
              </li>
              <li>Regdanvimab is not authorized with doses of 20 mg/kg and 80
                mg/kg.
              </li>
            </ul>
          </div>
        </div>
        <!---->
        <div class="cont-sec">
          <h3 class="sub-tit3">Efficacy</h3>
          <div class="cont-box cont-indt">
            <h4 class="sub-tit2">Proportion of patients progressing to severe
              COVID-19 up to Day 28</h4>
            <ul class="cont-list">
              <li>
                The hospitalisation (≥ 24 hours of acute care), oxygen therapy
                (at least 24 hours of supplemental oxygen care and SpO2 measure
                in room air before applying supplemental oxygen shows ≤94%) and
                mortality due to SARS-CoV-2 infection were identified.
              </li>
              <li>
                Progression of COVID-19 at Day 28, the primary endpoint, was <b>reduced
                  by 72% in high-risk patients</b> treated with regdanvimab
                compared to placebo (p&lt;0.0001).
              </li>
            </ul>
            <div class="table-wr">
              <table class="table-style01">
                <thead>
                <tr>
                  <th colspan="2"></th>
                  <th>regdanvimab 40mg/kg</th>
                  <th class="style02">Placebo</th>
                  <th class="style03">Reduction Rate</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                  <td class="cate" rowspan="2">Patients at High-Risk</td>
                  <td class="cate2">n/N (%)</td>
                  <td>14/446 (3.1%)</td>
                  <td>48/434 (11.1%)</td>
                  <td class="bd-blue" rowspan="2"
                      style="border-bottom:1px solid #dddddd!important;"><b
                      class="p-bl">72%</b></td>
                </tr>
                <tr>
                  <td class="cate2">p-value</td>
                  <td colspan="2">&lt;0.0001</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="2">All Patients</td>
                  <td class="cate2">n/N (%)</td>
                  <td>16/656 (2.4%)</td>
                  <td>53/659 (8.0%)</td>
                  <td class="bd-blue" rowspan="2"
                      style="border-top:0!important;"><b class="p-bl">70%</b>
                  </td>
                </tr>
                <tr>
                  <td class="cate2">p-value</td>
                  <td colspan="2">&lt;0.0001</td>
                </tr>
                </tbody>
              </table>
            </div>
            <p style="font-size:1.3rem;">
              The high-risk patients with 1 or more of the following risk
              factors: Age >50 years; BMI > 30 kg/m² collected via vital signs
              CRF; Cardiovascular disease, including hypertension; Chronic
              kidney disease, including those on dialysis; Chronic lung disease,
              including asthma; Non-severe pneumonia; Chronic metabolic disease,
              including diabetes; Chronic liver disease; and Immunosuppressed,
              based on investigator’s assessment.
            </p>
          </div>
        </div>
        <!---->
        <div class="cont-sec">
          <div class="cont-box cont-indt">
            <h4 class="sub-tit2 mg10">Time to <span class="p-bl">Clinical Recovery up to Day 14</span>
            </h4>
            <ul class="cont-list">
              <li>The median time to clinical recovery† in high-risk patients
                treated with regdanvimab was <b>9.3 days</b> which was at least
                <b>4.7 days shorter</b> than patients who received the placebo
                (p&lt;0.0001).
              </li>
              <li>
                The median time to clinical recovery† among all patients was
                also <b>4.9 days shorter</b> in patients who received
                regdanvimab than patients who received the placebo (p&lt;0.0001).
              </li>
            </ul>
            <div class="table-wr">
              <table class="table-style01">
                <thead>
                <tr>
                  <th colspan="2"></th>
                  <th>regdanvimab 40mg/kg</th>
                  <th class="style02">Placebo</th>
                  <th class="style03">Difference</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                  <td class="cate" rowspan="2">Patients at High-Risk</td>
                  <td class="cate2">Median, days</td>
                  <td>9.3</td>
                  <td>14.0*</td>
                  <td class="bd-blue" rowspan="2"
                      style="border-bottom:1px solid #dddddd!important;"><b
                      class="p-bl">4.7</b></td>
                </tr>
                <tr>
                  <td class="cate2">p-value</td>
                  <td colspan="2">&lt;0.0001</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="2">All Patients</td>
                  <td class="cate2">Median, Days</td>
                  <td>8.4</td>
                  <td>13.3</td>
                  <td class="bd-blue" rowspan="2"
                      style="border-top:0!important;"><b class="p-bl">4.9</b>
                  </td>
                </tr>
                <tr>
                  <td class="cate2">p-value</td>
                  <td colspan="2">&lt;0.0001</td>
                </tr>
                </tbody>
              </table>
              <p class="mgt20">*The number of patients who achieved clinical
                recovery up to Day 14 was less than 50%. The median was not
                reached in 14 days.</p>
            </div>

          </div>
        </div>
        <!---->
        <div class="cont-sec">
          <h3 class="sub-tit3">Mean (± SE) change from baseline of viral load
            titre (All patients)</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li class="p-bk">Greater reduction from baseline viral load were
                shown in the regdanvimab 40 mg/kg group compared to the placebo
                group at Day 7.
              </li>
            </ul>
            <div class="img-sec"><img src="/img/providers/graph_img02.jpg">
            </div>
          </div>
        </div>
        <!--
        <div class="cont-sec">
          <h3 class="sub-tit3" style="margin-left:0;">Time-Weighted Average Change from Baseline for Viral Shedding (in log<span class="s-txt v-btm">10</span>cp/mL) (Day 7 & Day 10)</h3>
          <div class="cont-box cont-indt">
            <ul class="cont-list">
              <li>At Day 7 and Day 10, regdanvimab group showed difference in viral shedding from placebo groups, and this result was statistically significant.</li>
            </ul>
            <div class="table-wr">
              <table class="table-style02">
                <colgroup>
                  <col width="20%">
                  <col width="20%">
                  <col width="20%">
                  <col width="20%">
                  <col width="20%">
                </colgroup>
                <thead>
                  <tr>
                    <th></th>
                    <th>regdanvimab 40mg/kg<br>(N=101)</th>
                    <th>regdanvimab 80mg/kg<br>(N=103)</th>
                    <th>Pooled regdanvimab</th>
                    <th>Placebo<br>(N=103)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="cate al-l" colspan="5">Time-Weighted Average Change from Baseline through Day 7</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">N</td>
                    <td>96</td>
                    <td>101</td>
                    <td>197</td>
                    <td>103</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">Least Square Mean (SE)</td>
                    <td>-1.72 (0.084)</td>
                    <td>-1.75 (0.082)</td>
                    <td>-1.74 (0.0065)</td>
                    <td>-1.33 (0.082)</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">95% CI</td>
                    <td>-1.33 (0.082)</td>
                    <td>-1.33 (0.082)</td>
                    <td>-1.87, -1.61</td>
                    <td>-1.49, -1.16</td>
                  </tr>
                  <tr>
                    <td class="cate al-l bd-blue" colspan="5">Difference vs Placebo by Day 7</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">Least Square Mean (SE)</td>
                    <td><b>-0.40 (0.104)</b></td>
                    <td><b>-0.43 (0.103)</b></td>
                    <td class="bd-blue" ><b>-0.41 (0.089)</b></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td class="cate al-l" >95% CI</td>
                    <td>-0.60, -0.19</td>
                    <td>-0.63, -0.22</td>
                    <td class="bd-blue" >-0.59, -0.24</td>
                    <td></td>
                  </tr>
                  <tr>
                    <td class="cate al-l">P-value</td>
                    <td>0.0002</td>
                    <td>&lt;0.0001</td>
                    <td class="bd-blue" ><b class="p-rd">&lt;0.0001</b></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td class="cate al-l bd-blue" colspan="5">Time-Weighted Average Change from Baseline through Day 10</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">N</td>
                    <td>96</td>
                    <td>101</td>
                    <td>197</td>
                    <td>103</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">Least Square Mean (SE)</td>
                    <td>-2.13 (0.085)</td>
                    <td>-2.21 (0.083)</td>
                    <td>-2.17 (0.065)</td>
                    <td>-1.78 (0.083)</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">95% CI</td>
                    <td>-2.30, -1.96</td>
                    <td>-2.37, -2.04</td>
                    <td>-2.30, -2.04</td>
                    <td>-1.94, -1.62</td>
                  </tr>
                  <tr>
                    <td class="cate al-l bd-blue"  colspan="5">Difference vs Placebo by Day 10</td>
                  </tr>
                  <tr>
                    <td class="cate al-l">Least Square Mean (SE)</td>
                    <td><b>-0.35 (0.105)</b></td>
                    <td><b>-0.43 (0.103)</b></td>
                    <td class="bd-blue" ><b>-0.39 (0.090)</b></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td class="cate al-l">95% CI</td>
                    <td>-0.56, -0.15</td>
                    <td>-0.63, -0.22</td>
                    <td class="bd-blue" >-0.57, -0.21</td>
                    <td></td>
                  </tr>
                  <tr>
                    <td class="cate al-l">P-value</td>
                    <td>0.0009</td>
                    <td>&lt;0.0001</td>
                    <td class="bd-blue" ><b class="p-rd">&lt;0.0001</b></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td class="cate al-l" colspan="5">Note: P-value from stratified log-rank test stratified by age (≥60 years vs. &lt;60 years), baseline comorbidities (Yes vs. No) and region are presented.<br> Patients who have negative or missing result at baseline and do not have positive at Day 2 are excluded in this analysis.</td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>-->
        <div class="cont-sec">
          <h3 class="sub-tit3">Safety</h3>
          <div class="cont-box cont-indt">
            <h4 class="sub-tit2">Summary of adverse events up to Day 28</h4>
            <ul class="cont-list">
              <li>There were no clinical meaningful differences between the
                safety results of the regdanvimab and the placebo groups.
              </li>
            </ul>
            <div class="table-wr">
              <table class="table-style01">
                <thead>
                <tr>
                  <th colspan="2">N(%)</th>
                  <th>regdanvimab 40 mg/kg (n=652)</th>
                  <th class="style02">Placebo (n=650)</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                  <td class="cate" rowspan="2">≥ 1 TEAE</td>
                  <td class="cate2">Total</td>
                  <td>198 (30.4)</td>
                  <td>202 (31.1)</td>
                </tr>
                <tr>
                  <td class="cate2">Related</td>
                  <td>44 (6.7)</td>
                  <td>46 (7.1)</td>
                </tr>
                <tr>
                  <td class="cate" rowspan="3">≥ 1 TESAE</td>
                  <td class="cate2">Total</td>
                  <td>4 (0.6)</td>
                  <td>1 (0.2)</td>
                </tr>
                <tr>
                  <td class="cate2">Related</td>
                  <td>1 (0.2)</td>
                  <td>0</td>
                </tr>
                <tr>
                  <td class="cate2">Unrelated</td>
                  <td>3 (0.5)</td>
                  <td>1 (0.2)</td>
                </tr>
                <tr>
                  <td class="cate">≥ 1 TEAE Classified as IRR*</td>
                  <td class="cate2">Total (=Related)</td>
                  <td>4 (0.6)</td>
                  <td>7 (1.1)</td>
                </tr>
                <tr>
                  <td class="cate">TEAEs Leading to Study Drug Discontinuation
                  </td>
                  <td class="cate2">Total</td>
                  <td>0</td>
                  <td>0</td>
                </tr>
                </tbody>
              </table>
              <p class="mgt20">*All events were grade 1 or 2, and all patients
                from both groups were recovered during the treatment period</p>
              <!--
              <table class="table-style02">
                <thead>
                  <tr>
                    <th colspan="2">Safety Population</th>
                    <th>regdanvimab 40 mg/kg (N=105)</th>
                    <th>regdanvimab 80 mg/kg (N=110)</th>
                    <th>regdanvimab Total (N=215)</th>
                    <th>Placebo (N=110)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="cate" rowspan="2">No. of patients<br>with 1+ Adverse Event (AE)</td>
                    <td>Total</td>
                    <td>31 (29.5)</td>
                    <td>27 (24.5)</td>
                    <td>58 (<b class="p-rd">27.0</b>)</td>
                    <td>34 (<b class="p-rd">30.9</b>)</td>
                  </tr>
                  <tr>
                    <td>Related</td>
                    <td>7 (6.7)</td>
                    <td>5 (4.5)</td>
                    <td>12 (<b class="p-rd">5.6</b>)</td>
                    <td>34 (<b class="p-rd">4.5</b>)</td>
                  </tr>
                  <tr>
                    <td class="cate">No. of patients with 1+ Serious Adverse Event</td>
                    <td>Total</td>
                    <td>0</td>
                    <td>0</td>
                    <td>0</td>
                    <td>0</td>
                  </tr>
                  <tr>
                    <td class="cate">Infusion Related Reaction</td>
                    <td>Total</td>
                    <td>1 (1.0)</td>
                    <td>0</td>
                    <td>1 <b class="p-rd">(0.5)</b></td>
                    <td>2 <b class="p-rd">(1.8)</b></td>
                  </tr>
                  <tr>
                    <td class="cate">Dropout Due to AE</td>
                    <td>Total</td>
                    <td>0</td>
                    <td>0</td>
                    <td>0</td>
                    <td>0</td>
                  </tr>
                </tbody>
              </table>-->
            </div>
            <ul class="cont-list">
              <li>The safety results confirmed that the regdanvimab was well
                tolerated and safety profile following regdanvimab
                administration did not show any unexpected safety issue.
              </li>
              <li>Overall rate of infusion related reaction was low and no
                treatment-emergent serious adverse events or deaths were
                reported during the study.
              </li>
              <li>The anti-drug antibody positive rate was low, and no
                suspicious antibody-dependent enhancement event was reported
                during the study.
              </li>
            </ul>
          </div>
        </div>
        <!---->
      </div>
    </section>
    <!--cont-f-->
  </section>
  <!--sec04-->
  <section id="sec05" class="cont-c el">
    <div class="inner">
      <h2 class="cont-tit">Neutralizing capability against emerging
        variants<span class="s-num">8-11</span></h2>
      <div class="cont-sec">
        <h3 class="sub-tit">In-vitro Plaque Reduction Neutralizing Test
          (PRNT)</h3>
        <ul class="cont-list cont-indt">
          <li>
            PRNT using authentic SARS-CoV-2 variant virus indicates that
            regdanvimab retained activity against the Alpha (0.56-fold change in
            IC<span class="s-txt v-btm">50</span> value), Zeta (2.16-fold change
            in IC<span class="s-txt v-btm">50</span> value), Iota (3.34-fold
            change in IC<span class="s-txt v-btm">50</span> value) and Eta
            (2.37-fold change in IC<span class="s-txt v-btm">50</span> value)
            variants.

          </li>
          <li>
            Microneutralisation data using authentic SARS-CoV-2 variant virus
            indicate that regdanvimab retains activity against the Alpha variant
            (1.4-fold change in IC<span class="s-txt v-btm">50</span> value) and
            reduced potency against the Beta (19.75-fold change in IC<span
              class="s-txt v-btm">50</span> value) and Gamma (137.88-fold change
            in IC<span class="s-txt v-btm">50</span> value) variants.
          </li>
        </ul>
      </div>

      <div class="cont-box cont-indt">
        <div class="table-wr">
          <table class="table-style01">
            <thead>
            <tr>
              <th>World Health<br>Organisation<br>(WHO) Label</th>
              <th>Lineage with<br>Spike Protein<br>Substitution</th>
              <th>Key Substitutions<br>Tested<span class="s-txt">a</span></th>
              <th>Fold Reduction<br>in Susceptibility<br>(Authentic Virus)</th>
              <th>Fold Reduction<br>in Susceptibility<br>(Pseudovirus)<span
                  class="s-txt"></span></th>
              <th>Animal Test<br>(Treatment Efficacy)</th>
            </tr>
            </thead>
            <tbody>
            <tr>
              <td class="cate">Alpha</td>
              <td class="cate">B.1.1.7</td>
              <td class="cate">N501Y</td>
              <td class="cate">No change<span class="s-txt">b, d, e</span></td>
              <td class="cate">No change<span class="s-txt">b</span></td>
              <td class="cate">-</td>
            </tr>
            <tr>
              <td>Beta</td>
              <td>B.1.351</td>
              <td>K417N+E484K+N501Y</td>
              <td>19.75<span class="s-txt">e</span> / 310.06<span class="s-txt">d</span>
              </td>
              <td>96.80</td>
              <td>Similar with wild-type<span class="s-txt">10</span></td>
            </tr>
            <tr>
              <td class="cate">Gamma</td>
              <td class="cate">P.1</td>
              <td class="cate">K417T+E484K+N501Y</td>
              <td class="cate">167.90<span class="s-txt">d</span></td>
              <td class="cate">35.58</td>
              <td class="cate">Similar with wild-type<span
                  class="s-txt">11</span></td>
            </tr>
            <tr>
              <td>Delta</td>
              <td>B.1.167.2</td>
              <td>L452R/T478K/P681R</td>
              <td>182.99<span class="s-txt">d</span></td>
              <td>27.70</td>
              <td>Similar with wild-type<span class="s-txt">12</span></td>
            </tr>
            <tr>
              <td class="cate">Epsilon</td>
              <td class="cate">B.1.427</td>
              <td class="cate">L452R</td>
              <td class="cate">73.89<span class="s-txt">d</span></td>
              <td class="cate">34.97</td>
              <td class="cate">-</td>
            </tr>
            <tr>
              <td>Epsilon</td>
              <td>B.1.429</td>
              <td>L452R</td>
              <td>54.08<span class="s-txt">d</span></td>
              <td>34.97</td>
              <td>-</td>
            </tr>
            <tr>
              <td class="cate">Zeta</td>
              <td class="cate">P.2</td>
              <td class="cate">E484K</td>
              <td class="cate">No change<span class="s-txt">b, d</span></td>
              <td class="cate">8.66</td>
              <td class="cate">-</td>
            </tr>
            <tr>
              <td>Eta</td>
              <td>B.1.525</td>
              <td>E484K</td>
              <td>No change<span class="s-txt">b, d</span></td>
              <td>No change<span class="s-txt">b</span></td>
              <td>-</td>
            </tr>
            <tr>
              <td class="cate">lota</td>
              <td class="cate">B.1.526<span class="s-txt">c</span></td>
              <td class="cate">E484K</td>
              <td class="cate">No change<span class="s-txt">b, d</span></td>
              <td class="cate">No change<span class="s-txt">b</span></td>
              <td class="cate">-</td>
            </tr>
            <tr>
              <td>Kappa</td>
              <td>B.1.617.1</td>
              <td>L452R+E484Q+P681R</td>
              <td>23.89<span class="s-txt">d</span></td>
              <td>29.31</td>
              <td>-</td>
            </tr>
            </tbody>
          </table>
          <p style="margin-top:1em;"><span class="s-txt">a</span>For variants
            with more than one substitution of concern, only the one(s) with the
            greatest impact on activity is(are) listed</p>
          <p><span class="s-txt">b</span>No change: &lt;5-fold reduction in
            susceptibility</p>
          <p><span class="s-txt">c</span>Not all isolates of the Iota lineage
            harbors E484K substitution (as of February 2021)</p>
          <p><span class="s-txt">d</span>The study was conducted using plaque
            reduction neutralisation test</p>
          <p><span class="s-txt">e</span>The study was conducted using
            microneutralisation assay</p>
          <p><span class="s-txt">f</span>Key substitutions for global variants
            have been tested in a pseudovirus assay</p>
        </div>
      </div>

    </div>
  </section>
  <!--sec05-->
  <section id="sec06" class="cont-d el">
    <div class="cont-sec inner">
      <h2 class="cont-tit">Neutralizing capability against emerging
        variants(In-vivo Animal Studies)</h2>
      <div class="cont-sec">
        <h3 class="sub-tit p-gr">In vivo Efficacy Test Against Beta (B.1.351)
          Variant<span style="font-size:1.4rem;">9</span></h3>
        <ul class="cont-list cont-indt mg20">
          <li>
            Therapeutic dosage of regdanvimab showed in vivo neutralising
            potency against the Beta (B.1.351) variant in the ferret challenge
            study.
          </li>
          <li>
            Virus titres in the upper respiratory tract significantly decreased
            following regdanvimab treatment similarly for both viruses (Beta and
            S clades) in the TCID50 assay, where only the replicating virus is
            quantified.
          </li>
        </ul>
        <div class="cont-box cont-indt" style="text-align:center;">
          <img src="/img/providers/mono_g01.png">
        </div>
      </div>
    </div>
    <div class="cont-sec inner">
      <h3 class="sub-tit p-gr">In vivo Efficacy Test Against Gamma (P.1) Variant<span
          class="s-txt">10</span></h3>
      <ul class="cont-list cont-indt mg20">
        <li>Regdanvimab showed a significant decrease in viral load in the lungs
          of hACE2 TG mice 8 hours after viral challenge
        </li>
        <li>All the mice treated with regdanvimab showed LOQ in viral load at 6
          dpi.
        </li>
      </ul>
      <div class="cont-box cont-indt" style="text-align:center;">
        <img src="/img/providers/mono_g02.png">
      </div>
      <ul class="cont-list cont-indt mg20">
        <li>During the follow-up period, mice treated with regdanvimab showed
          significant protection from weight loss from 2 dpi.
        </li>
      </ul>
      <div class="cont-box cont-indt" style="text-align:center;">
        <img src="/img/providers/mono_g03.png">
      </div>
      <ul class="cont-list cont-indt mg20">
        <li>100% survival rates were observed in mice treated with regdanvimab,
          while mice treated with placebo showed 0% survival rate from 6 dpi.
        </li>
      </ul>
      <div class="cont-box cont-indt mg20" style="text-align:center;">
        <img src="/img/providers/mono_g04.png">
      </div>
    </div>
    <div class="cont-sec inner">
      <h3 class="sub-tit p-gr">In vivo Efficacy Test Against Delta (B.1.167.2)
        Variant<span class="s-txt">11</span></h3>
      <ul class="cont-list cont-indt mg20">
        <li>Regdanvimab showed significant decrease in viral load in the lungs
          of mice 8 hours after viral challenge, with virus eradication from all
          mice treated with 20 mg/kg and 80 mg/kg at 3 dpi.
        </li>
        <li>All the mice treated with regdanvimab 5 to 80 mg/kg (clinically
          equivalent to 2.5 to 40 mg/kg for human dose) showed LOQ in viral load
          at 6 dpi.
        </li>
      </ul>
      <div class="cont-box cont-indt mg20" style="text-align:center;">
        <img src="/img/providers/mono_g05.png">
      </div>
      <ul class="cont-list cont-indt mg20">
        <li>During the follow-up period, mice treated with regdanvimab showed
          significant protection from weight loss at 3 dpi and thereafter.
        </li>
      </ul>
      <div class="cont-box cont-indt mg20" style="text-align:center;">
        <img src="/img/providers/mono_g06.png">
      </div>
      <ul class="cont-list cont-indt mg20">
        <li>100% survival rates were observed in mice treated with regdanvimab,
          while mice treated with placebo showed 0% survival rate from 6 dpi.
        </li>
      </ul>
      <div class="cont-box cont-indt mg20" style="text-align:center;">
        <img src="/img/providers/mono_g07.png">
      </div>
    </div>
  </section>
  <!--sec06-->
  <section id="sec07" class="cont-c el">
    <div class="inner">
      <h2 class="cont-tit">References</h2>
      <ul class="nb-list">
        <li>
          <span>1.</span>
          NCT: National Clinical Trial.
          https://clinicaltrials.gov/ct2/show/NCT04525079.
        </li>
        <li>
          <span>2.</span>
          Kim J et al. CT-P59, a monoclonal antibody against SARS-CoV-2 spike
          protein, proved therapeutic efficacy safety in clinical studies
          conducted in healthy subjects and mild COVID-19 patients. The 2020
          Fall Conference of the Korean Society of Infectious Diseases; Limited
          Access.
        </li>
        <li>
          <span>3.</span>
          Kim S et al. CT-P59, a monoclonal antibody against SARS-CoV-2 spike
          protein, proved therapeutic efficacy safety in clinical studies
          conducted in healthy subjects and mild COVID-19 patients. The 2020
          Fall Conference of the Korean Society for Clinical Pharmacology &
          Therapeutics; Limited Access.
        </li>
        <li>
          <span>4.</span>
          NCT: National Clinical Trial. <a
            href="https://clinicaltrials.gov/ct2/show/NCT04602000"
            target="_blank">https://clinicaltrials.gov/ct2/show/NCT04602000</a>
        </li>
        <li>
          <span>5.</span>
          Kim JY, et al. Clinical Therapeutics, Safety, Virologic Efficacy, and
          Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against
          SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized,
          Placebo-Controlled Phase 1 Studies in Healthy Subjects and Patients
          with Mild SARS-CoV-2 Infection,
          <a href="https://doi.org/10.1016/j.clinthera.2021.08.009"
             target="_blank">https://doi.org/10.1016/j.clinthera.2021.08.009</a>
        </li>
        <li>
          <span>6.</span>
          Eom J et al. Therapeutic Effect of Regdanvimab (CT-P59) in Patients
          with Mild to Moderate Symptoms of SARSCoV-2 Infection: Day 28 Results
          from a Multicentre, Randomised Controlled Pivotal Trial. 2020 High1
          Symposia; Limited Access.
        </li>
        <li>
          <span>7.</span>
          Ison MG et al. Therapeutic Effect of Regdanvimab (CT-P59) in Patients
          with Mild to Moderate Symptoms of SARSCoV-2 Infection: Day 28 Results
          from a Multicentre, Randomised Controlled Pivotal Trial. 2020 Virtual
          Keystone Symposia; Limited Access.
        </li>
        <li>
          <span>8.</span>
          Ison MG et al. Therapeutic effect of regdanvimab in patients with mild
          to moderate COVID-19: day 28 results from a multi-centre, randomised,
          controlled pivotal trial. 31st European Congress of Clinical
          Microbiology & Infectious Diseases.
        </li>
        <li>
          <span>9.</span>
          Data on file. Celltrion Healthcare.
        </li>
        <li>
          <span>10.</span>
          Ryu DK, et al. Biochem Biophys Res Commun. 2021;556:135-140.
        </li>
        <li>
          <span>11.</span>
          Ryu DK, et al. bioRxiv., Therapeutic efficacy of CT-P59 against P.1
          variant of SARS-CoV-2, Posted July 09, 2021. [Preprint]
        </li>
        <li>
          <span>12.</span>
          Ryu DK, et al. bioRxiv., The in vitro and in vivo potency of CT-P59
          against Delta and its associated variants of SARS-CoV-2, Posted July
          23, 2021. [Preprint]
        </li>
      </ul>
    </div>
  </section>
  <!--sec07-->
</div> 
